Central Nervous System Vascular Malformations: Clinical Trials

7 trials for Central Nervous System Vascular Malformations, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 recruiting, 1 terminated, 1 unknown. 7 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 3, Recruiting 2, Terminated 1, Unknown 1
Phase 11Completed 1
Phase 31Recruiting 1

Follow Central Nervous System Vascular Malformations: new trials by email Literature Review of Central Nervous System Vascular Malformations trials Research Report on Central Nervous System Vascular Malformations

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations
Bevacizumab, Placebo - Cerebral AV Malformation
Phase 2 / Phase 3RecruitingFondation Ophtalmologique Adolphe de Rothschild542026-01-162026-01-22
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
REC-994, Placebo - Cerebral Cavernous Malformation
Phase 2CompletedRecursion Pharmaceuticals Inc.622022-03-172026-10-22
Lovastatin for Treatment of Brain Arteriovenous Malformations
Lovastatin, Placebo - Cerebral Arteriovenous Malformation
Phase 2UnknownBeijing Tiantan Hospital12442021-01-012020-03-09
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions
Cognitive Sparing Brain Stereotactic Radiosurgery (SRS) - Brain Metastases, Adult, Neurocognitive Function
Phase 2RecruitingJona Hattangadi-Gluth902019-05-012026-09-08
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Atorvastatin, Placebo - Cerebral Cavernous Malformation
Phase 1 / Phase 2CompletedUniversity of Chicago802018-07-172025-08-22
Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation
Propranolol - Cerebral Cavernous Malformation
Phase 2CompletedMario Negri Institute for Pharmacological Research712018-04-112022-02-25
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
Propranolol, DNA and RNA Analysis - Cerebral Cavernous Malformations
Phase 2TerminatedSt. Joseph's Hospital and Medical Center, Phoenix42018-01-242024-04-19

Narrower conditions

Hemangioma, Cavernous, Central Nervous System (4)  ·  Intracranial Arteriovenous Malformations (3)  ·  Brain Neoplasms (1)  ·  Meningioma (1)  ·  Neoplasms (1)

Broader conditions

Brain Diseases (7)  ·  Cardiovascular Abnormalities (7)  ·  Cardiovascular Diseases (7)  ·  Central Nervous System Diseases (7)  ·  Congenital Abnormalities (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Nervous System Diseases (7)  ·  Nervous System Malformations (7)  ·  Vascular Diseases (7)  ·  Vascular Malformations (7)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms, Vascular Tissue (5)  ·  Cavernous Sinus Syndromes (4)  ·  Hemangioma (4)

Interventions

Propranolol (2)  ·  Atorvastatin (1)  ·  Bevacizumab (1)  ·  DNA (1)  ·  Lovastatin (1)

Sponsors

Beijing Tiantan Hospital (1)  ·  Fondation Ophtalmologique Adolphe de Rothschild (1)  ·  Jona Hattangadi-Gluth (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Recursion Pharmaceuticals Inc. (1)  ·  St. Joseph's Hospital and Medical Center, Phoenix (1)  ·  University of Chicago (1)

Countries

United States (4)  ·  China (1)  ·  France (1)  ·  Italy (1)

Top investigators

Daniel F Hanley, MD (1)  ·  Elisabetta Dejana, Professor (1)  ·  Issam A Awad, MD (1)  ·  Jona Hattangadi-Gluth, MD (1)  ·  Joseph Zabramski, MD (1)  ·  Roberto Latini (1)

Results publications

PMID 32398113, PMID 36403580, PMID 38419711, PMID 40120614, PMID 40570636, PMID 41117517, PMID 41608890

NIH funding

2017 (1), R01CA238783 (1)